Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025

Angela M.C. Rose; Héloïse Lucaccioni; Kimberly Marsh; Freja Kirsebom; Heather Whitaker; Hanne Dorthe Emborg; Amanda Bolt Botnen; Mark G. O’Doherty; Francisco Pozo; Safraj Shahul Hameed; Nick Andrews; Mark Hamilton; Ramona Trebbien; Karina Lauenborg Møller; Diogo F.P. Marques; Ross McQueenie; Jamie Lopez-Bernal; Simon Cottrell; Magda Bucholc; Esther Kissling; Anna Parys; Arne Witdouck; Benedicte Delaere; Benédicte Lissoir; Catherine Quoidbach; Catherine Sion; Claire Brugerolles; Deborah De Geyter; Dylan Lievens; Eva Bernaert; Eveline Van Honacker; Evelyn Petit; Francesco Genderini; François Dufrasne; Isabel Leroux-Roels; Katelijne Flore; Katty Renard; Koen Magerman; Laurane De Mot; Lucie Seyler; Marc Bourgeois; Marieke Bleyen; Marie Pierre Parsy; Marijke Reynders; Marlies Blommen; Mathil Vandromme; Melanie Delvallee; Natasja Detillieu; Nathalie Bossuyt; Nicolas Dauby

doi:10.2807/1560-7917.ES.2025.30.7.2500102

Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025

Angela M.C. Rose
, Héloïse Lucaccioni
, Kimberly Marsh
, Freja Kirsebom
, Heather Whitaker
, Hanne Dorthe Emborg
, Amanda Bolt Botnen
, Mark G. O’Doherty
, Francisco Pozo
, Safraj Shahul Hameed
, Nick Andrews
, Mark Hamilton
, Ramona Trebbien
, Karina Lauenborg Møller
, Diogo F.P. Marques
, Ross McQueenie
, Jamie Lopez-Bernal
, Simon Cottrell
, Magda Bucholc
, Esther Kissling

Anna Parys, Arne Witdouck, Benedicte Delaere, Benédicte Lissoir, Catherine Quoidbach, Catherine Sion, Claire Brugerolles, Deborah De Geyter, Dylan Lievens, Eva Bernaert, Eveline Van Honacker, Evelyn Petit, Francesco Genderini, François Dufrasne, Isabel Leroux-Roels, Katelijne Flore, Katty Renard, Koen Magerman, Laurane De Mot, Lucie Seyler, Marc Bourgeois, Marieke Bleyen, Marie Pierre Parsy, Marijke Reynders, Marlies Blommen, Mathil Vandromme, Melanie Delvallee, Natasja Detillieu, Nathalie Bossuyt, Nicolas Dauby

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

81 Downloads (Pure)

Abstract

The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1) pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32–53% in primary care and 33–56% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened.

Original language	English
Pages (from-to)	9-19
Number of pages	11
Journal	Eurosurveillance
Volume	30
Issue number	7
Early online date	20 Feb 2025
DOIs	https://doi.org/10.2807/1560-7917.ES.2025.30.7.2500102
Publication status	Published (in print/issue) - 20 Feb 2025

Bibliographical note

Publisher Copyright:
© 2025 European Centre for Disease Prevention and Control (ECDC). All rights reserved.

Funding

Aukse Mickiene has received a grant for the Independent Investigator Initiated Research (Project Code/PO/Tracking Number WI236259; Grant ID#53233947); Pfizer R&D Investigator-Initiated Research program (https://www. pfizer.com/science/collaboration/investigator-initiated-research) for the scientific project “A prospective study on the long-term outcome and pathogenesis of tick-borne encephalitis”, and a Grant from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infectious Diseases of the Brain (ESGIB); sponsorship for participation in the international scientific conferences by MSD, Pfizer, Abbvie, Janssen, payments for lectures in local scientific conferences and consultation fees from GSK, Sanofi, Pfizer, E-visit. Ligita Jancoriene has received honoraria fees for lectures from Pfizer, Viatris, Swixx Biopharma. The EU-H study and EU-PC received funding from the European Centre for Disease Prevention and Control under framework contract ECDC/2021/016 and ECDC/2021/019, respectively.

Funders	Funder number
Sanofi
European Society of Clinical microbiology and Infectious Diseases
AbbVie
Pfizer
European Centre for Disease Prevention and Control	ECDC/2021/019, ECDC/2021/016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.2807/1560-7917.ES.2025.30.7.2500102

eurosurv-30-7-2Final published version, 830 KBLicence: CC BY

Cite this

Rose, A. M. C., Lucaccioni, H., Marsh, K., Kirsebom, F., Whitaker, H., Emborg, H. D., Botnen, A. B., O’Doherty, M. G., Pozo, F., Hameed, S. S., Andrews, N., Hamilton, M., Trebbien, R., Møller, K. L., Marques, D. F. P., McQueenie, R., Lopez-Bernal, J., Cottrell, S., Bucholc, M., ... Dauby, N. (2025). Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025. Eurosurveillance, 30(7), 9-19. https://doi.org/10.2807/1560-7917.ES.2025.30.7.2500102

@article{ce7cbd2d3de64b2584a7db1405cf81de,

title = "Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025",

abstract = "The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1) pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32–53\% in primary care and 33–56\% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58\% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened.",

author = "Rose, \{Angela M.C.\} and H{\'e}lo{\"i}se Lucaccioni and Kimberly Marsh and Freja Kirsebom and Heather Whitaker and Emborg, \{Hanne Dorthe\} and Botnen, \{Amanda Bolt\} and O{\textquoteright}Doherty, \{Mark G.\} and Francisco Pozo and Hameed, \{Safraj Shahul\} and Nick Andrews and Mark Hamilton and Ramona Trebbien and M{\o}ller, \{Karina Lauenborg\} and Marques, \{Diogo F.P.\} and Ross McQueenie and Jamie Lopez-Bernal and Simon Cottrell and Magda Bucholc and Esther Kissling and Anna Parys and Arne Witdouck and Benedicte Delaere and Ben{\'e}dicte Lissoir and Catherine Quoidbach and Catherine Sion and Claire Brugerolles and \{De Geyter\}, Deborah and Dylan Lievens and Eva Bernaert and \{Van Honacker\}, Eveline and Evelyn Petit and Francesco Genderini and Fran{\c c}ois Dufrasne and Isabel Leroux-Roels and Katelijne Flore and Katty Renard and Koen Magerman and \{De Mot\}, Laurane and Lucie Seyler and Marc Bourgeois and Marieke Bleyen and Parsy, \{Marie Pierre\} and Marijke Reynders and Marlies Blommen and Mathil Vandromme and Melanie Delvallee and Natasja Detillieu and Nathalie Bossuyt and Nicolas Dauby",

year = "2025",

month = feb,

day = "20",

doi = "10.2807/1560-7917.ES.2025.30.7.2500102",

language = "English",

volume = "30",

pages = "9--19",

journal = "Eurosurveillance",

issn = "1025-496X",

publisher = "European Centre for Disease Prevention and Control (ECDC)",

number = "7",

}

Rose, AMC, Lucaccioni, H, Marsh, K, Kirsebom, F, Whitaker, H, Emborg, HD, Botnen, AB, O’Doherty, MG, Pozo, F, Hameed, SS, Andrews, N, Hamilton, M, Trebbien, R, Møller, KL, Marques, DFP, McQueenie, R, Lopez-Bernal, J, Cottrell, S, Bucholc, M, Kissling, E, Parys, A, Witdouck, A, Delaere, B, Lissoir, B, Quoidbach, C, Sion, C, Brugerolles, C, De Geyter, D, Lievens, D, Bernaert, E, Van Honacker, E, Petit, E, Genderini, F, Dufrasne, F, Leroux-Roels, I, Flore, K, Renard, K, Magerman, K, De Mot, L, Seyler, L, Bourgeois, M, Bleyen, M, Parsy, MP, Reynders, M, Blommen, M, Vandromme, M, Delvallee, M, Detillieu, N, Bossuyt, N & Dauby, N 2025, 'Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025', Eurosurveillance, vol. 30, no. 7, pp. 9-19. https://doi.org/10.2807/1560-7917.ES.2025.30.7.2500102

TY - JOUR

T1 - Interim 2024/25 influenza vaccine effectiveness

T2 - eight European studies, September 2024 to January 2025

AU - Rose, Angela M.C.

AU - Lucaccioni, Héloïse

AU - Marsh, Kimberly

AU - Kirsebom, Freja

AU - Whitaker, Heather

AU - Emborg, Hanne Dorthe

AU - Botnen, Amanda Bolt

AU - O’Doherty, Mark G.

AU - Pozo, Francisco

AU - Hameed, Safraj Shahul

AU - Andrews, Nick

AU - Hamilton, Mark

AU - Trebbien, Ramona

AU - Møller, Karina Lauenborg

AU - Marques, Diogo F.P.

AU - McQueenie, Ross

AU - Lopez-Bernal, Jamie

AU - Cottrell, Simon

AU - Bucholc, Magda

AU - Kissling, Esther

AU - Parys, Anna

AU - Witdouck, Arne

AU - Delaere, Benedicte

AU - Lissoir, Benédicte

AU - Quoidbach, Catherine

AU - Sion, Catherine

AU - Brugerolles, Claire

AU - De Geyter, Deborah

AU - Lievens, Dylan

AU - Bernaert, Eva

AU - Van Honacker, Eveline

AU - Petit, Evelyn

AU - Genderini, Francesco

AU - Dufrasne, François

AU - Leroux-Roels, Isabel

AU - Flore, Katelijne

AU - Renard, Katty

AU - Magerman, Koen

AU - De Mot, Laurane

AU - Seyler, Lucie

AU - Bourgeois, Marc

AU - Bleyen, Marieke

AU - Parsy, Marie Pierre

AU - Reynders, Marijke

AU - Blommen, Marlies

AU - Vandromme, Mathil

AU - Delvallee, Melanie

AU - Detillieu, Natasja

AU - Bossuyt, Nathalie

AU - Dauby, Nicolas

PY - 2025/2/20

Y1 - 2025/2/20

N2 - The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1) pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32–53% in primary care and 33–56% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened.

AB - The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1) pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32–53% in primary care and 33–56% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened.

UR - https://www.scopus.com/pages/publications/85218993676

U2 - 10.2807/1560-7917.ES.2025.30.7.2500102

DO - 10.2807/1560-7917.ES.2025.30.7.2500102

M3 - Article

C2 - 39980423

AN - SCOPUS:85218993676

SN - 1025-496X

VL - 30

SP - 9

EP - 19

JO - Eurosurveillance

JF - Eurosurveillance

IS - 7

ER -

Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025

Abstract

Bibliographical note

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this